Kyverna Therapeutics, Inc. Files 2023 Annual Report on Form 10-K
Ticker: KYTX · Form: 10-K · Filed: Mar 26, 2024 · CIK: 1994702
Sentiment: neutral
Topics: 10-K, Annual Report, Kyverna Therapeutics, KYTX, Biotechnology
TL;DR
<b>Kyverna Therapeutics, Inc. has filed its 2023 Form 10-K, detailing its financial performance and corporate status.</b>
AI Summary
Kyverna Therapeutics, Inc. (KYTX) filed a Annual Report (10-K) with the SEC on March 26, 2024. Kyverna Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Emeryville, CA. Kyverna Therapeutics' common stock trades on The Nasdaq Stock Market LLC under the symbol KYTX. The company has elected to use the extended transition period for complying with new or revised financial accounting standards. Kyverna Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Why It Matters
For investors and stakeholders tracking Kyverna Therapeutics, Inc., this filing contains several important signals. This filing provides investors with a comprehensive overview of Kyverna Therapeutics' financial health, operational activities, and strategic direction for the fiscal year 2023. As an emerging growth company, Kyverna Therapeutics' filing may contain information relevant to understanding its development stage and future growth prospects in the biotechnology sector.
Risk Assessment
Risk Level: low — Kyverna Therapeutics, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate negative news or significant financial distress indicators.
Analyst Insight
Monitor future filings for updates on clinical trial progress and financial results, which will be key drivers for KYTX stock.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reported fiscal year end)
- 2024-03-26 — Filing Date (Date the 10-K was filed)
- 001-41947 — SEC File Number (Commission file number for the registrant)
- 83-1365411 — IRS Number (Registrant's IRS Employer Identification Number)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant name
- 001-41947 (other) — Commission File Number
- 5980 Horton Street (other) — Business Address
- Emeryville, CA (other) — Business Address City/State
- The Nasdaq Stock Market LLC (company) — Exchange where common stock is registered
- KYTX (ticker) — Trading Symbol
FAQ
When did Kyverna Therapeutics, Inc. file this 10-K?
Kyverna Therapeutics, Inc. filed this Annual Report (10-K) with the SEC on March 26, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Kyverna Therapeutics, Inc. (KYTX).
Where can I read the original 10-K filing from Kyverna Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Kyverna Therapeutics, Inc..
What are the key takeaways from Kyverna Therapeutics, Inc.'s 10-K?
Kyverna Therapeutics, Inc. filed this 10-K on March 26, 2024. Key takeaways: Kyverna Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The company is incorporated in Delaware and its principal executive offices are located in Emeryville, CA.. Kyverna Therapeutics' common stock trades on The Nasdaq Stock Market LLC under the symbol KYTX..
Is Kyverna Therapeutics, Inc. a risky investment based on this filing?
Based on this 10-K, Kyverna Therapeutics, Inc. presents a relatively low-risk profile. The filing is a standard annual report (10-K) and does not contain immediate negative news or significant financial distress indicators.
What should investors do after reading Kyverna Therapeutics, Inc.'s 10-K?
Monitor future filings for updates on clinical trial progress and financial results, which will be key drivers for KYTX stock. The overall sentiment from this filing is neutral.
How does Kyverna Therapeutics, Inc. compare to its industry peers?
Kyverna Therapeutics operates in the biotechnology sector, focusing on the development of novel therapies.
Are there regulatory concerns for Kyverna Therapeutics, Inc.?
The company is subject to standard SEC reporting requirements for public companies, including the filing of annual reports.
Industry Context
Kyverna Therapeutics operates in the biotechnology sector, focusing on the development of novel therapies.
Regulatory Implications
The company is subject to standard SEC reporting requirements for public companies, including the filing of annual reports.
What Investors Should Do
- Review the full 10-K filing for detailed financial statements and business operations.
- Analyze Kyverna Therapeutics' disclosures regarding its product pipeline and clinical development.
- Track future SEC filings for material updates on the company's progress and financial health.
Year-Over-Year Comparison
This is the initial 10-K filing for the fiscal year ended December 31, 2023, following the company's public offering.
Filing Stats: 4,393 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-03-26 16:40:23
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
- $22.00 — ommon stock at a price to the public of $22.00 per share, including the exercise in fu
- $366.9 million — n stock, and received gross proceeds of $366.9 million. Net proceeds were approximately $336.2
- $336.2 m — illion. Net proceeds were approximately $336.2 million, after deducting underwriting dis
- $80 billion — une disease therapies were greater than $80 billion globally in 2021. Despite the availabil
Filing Documents
- kytx_10k_2023_1231.htm (10-K) — 2929KB
- kytx-ex4_2.htm (EX-4.2) — 70KB
- kytx-ex23_1.htm (EX-23.1) — 3KB
- kytx-ex31_1.htm (EX-31.1) — 15KB
- kytx-ex31_2.htm (EX-31.2) — 15KB
- kytx-ex32_1.htm (EX-32.1) — 10KB
- kytx-ex32_2.htm (EX-32.2) — 10KB
- kytx-ex97.htm (EX-97) — 57KB
- img195371039_0.jpg (GRAPHIC) — 265KB
- img195371039_1.jpg (GRAPHIC) — 27KB
- img195371039_2.jpg (GRAPHIC) — 1137KB
- img195371039_3.jpg (GRAPHIC) — 265KB
- img195371039_4.jpg (GRAPHIC) — 201KB
- img195371039_5.jpg (GRAPHIC) — 36KB
- img195371039_6.jpg (GRAPHIC) — 147KB
- img195371039_7.jpg (GRAPHIC) — 782KB
- img195371039_8.jpg (GRAPHIC) — 594KB
- img195371039_9.jpg (GRAPHIC) — 614KB
- img195371039_10.jpg (GRAPHIC) — 113KB
- img195371039_11.jpg (GRAPHIC) — 1365KB
- img195371039_12.jpg (GRAPHIC) — 1221KB
- img195371039_13.jpg (GRAPHIC) — 285KB
- img195371039_14.jpg (GRAPHIC) — 150KB
- img195371039_15.jpg (GRAPHIC) — 44KB
- img195371039_16.jpg (GRAPHIC) — 51KB
- img195371039_17.jpg (GRAPHIC) — 658KB
- img195371039_18.jpg (GRAPHIC) — 561KB
- img195371039_19.jpg (GRAPHIC) — 196KB
- img195371039_20.jpg (GRAPHIC) — 998KB
- img195371039_21.jpg (GRAPHIC) — 1KB
- 0000950170-24-036481.txt ( ) — 15943KB
Business
Business 1 Item 1A.
Risk Factors
Risk Factors 49 Item 1B. Unresolved Staff Comments 114 Item 1C. Cybersecurity 114 Item 2.
Properties
Properties 115 Item 3.
Legal Proceedings
Legal Proceedings 115 Item 4. Mine Safety Disclosures 115 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 116 Item 6. [Reserved] 117 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 118 Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 133 Item 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 134 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 134 Item 9A.
Controls and Procedures
Controls and Procedures 134 Item 9B. Other Information 135 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 135 PART III Item 10. Directors, Executive Officers and Corporate Governance 136 Item 11.
Executive Compensation
Executive Compensation 141 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 148 Item 13. Certain Relationships and Related Transactions, and Director Independence 151 Item 14. Principal Accounting Fees and Services 155 PART IV Item 15. Exhibits, Financial Statement Schedules 156 Item 16. Form 10-K Summary 157 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements about us and our industry within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, plans for manufacturing, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limi